Rubicon Research Life IPO Subscription Day 3

Mon Oct 13 2025

Here is the final call for the Rubicon Research Life IPO launched on 9th October 2025. The bidding for the issue will close today, on 13th October 2025. The primary aim of the Rubicon Research Life IPO is to raise ₹1,377.50 crores from the market. Also, the Rubicon Research Life IPO has received strong subscription, indicating that shares will be listed at an impressive premium. Scroll down to check the Rubicon Research Life IPO subscription and details.

Table of Contents

Rubicon Research Life IPO Details

IPO Open Date	9th October 2025
Face Value	₹1 per share
Price Band	₹461 to ₹485 per share
Lot Size	30 shares
Issue Type	Bookbuilding IPO
Listing At	BSE & NSE
IPO Close Date	13th October 2025
Listing Date	16th October 2025

The price band for the Rubicon Research Life IPO has been set at ₹461 to ₹485 per share, with a total of 2,84,02,040 shares issued. Let’s segregate the share quota fixed for different categories of investors.

Investor Categories	Shares Offered	% of shares offered
QIB Shares Offered	2,12,71495	74.89%
NII Shares Offered	42,54,299	14.98%
Retail Shares Offered	28,36,200	9.99%
Employee Shares Offered	40,046	0.14%
Total Shares Offered	2,84,02,042	100.00%

Rubicon Research Life IPO Subscription Status

As of now, the Rubicon Research Life IPO has been subscribed to 108.80 times. Of these, 34.85 times are subscribed by retail investors, 102.40 times by non-institutional investors, and 137.09 times by QII (Qualified Institutional Investors).

The healthy subscription status indicates that investors are expecting higher returns at the time of the Rubicon Research Life IPO listing on 16th October 2025. Rubicon Research Life’s IPO also has a positive outlook, with a fresh issue of 1.03 crore shares to raise around Rs 1,377.50 crores.

Rubicon Research Life IPO GMP Today

We know that higher subscription levels drive grey-market premiums for IPOs. Let’s explore the Rubicon Research Life IPO GMP for 13th October 2025.

The grey market premium for this IPO is 21.44% or Rs 104 per share. It indicates that the estimated listing price per share is Rs 589. Numerous factors played a pivotal role in this jump in the GMP of Rubicon Research Life’s IPO. These include higher subscription rates, favourable market sentiment, and investors’ positive attitude towards IPOs.

GMP Date	IPO Price	GMP	Estimated Listing Price	Estimated Listing Gains
13-10-2025	₹485.00	₹104.00	₹589.00	21.44%
12-10-2025	₹485.00	₹96.00	₹581.00	19.79%
11-10-2025	₹485.00	₹110	₹595	22.68%
10-10-2025	₹485.00	₹111.00	₹596.00	22.89%
9-10-2025	₹485.00	₹100.00	₹585.00	20.62%
8-10-2025	₹485.00	₹98.00	₹538.00	20.21%
7-10-2025	₹485.00	₹80.00	₹565.00	16.49%
6-10-2025	₹485.00	₹80.00	₹565.00	16.49%
5-10-2025	₹485.00	₹60.00	₹553.00	14.02%
4-10-2025	₹485.00	₹60.00	₹553.00	14.02%
3-10-2025	₹485.00	₹0.00	₹485.00	0.00%
2-10-2025	₹485.00	₹0.00	₹485.00	0.00%

About Rubicon Research Life IPO Ltd.

Rubicon Research Limited, established in 1999, is a pharmaceutical company engaged in the development, manufacturing, and commercialisation of differentiated formulations. As of June 30, 2025, Rubicon Research had a portfolio of 72 active Abbreviated New Drug Application (ANDA) and New Drug Application (NDA) products approved by the US FDA. The company’s portfolio includes 66 commercialised products, with a US generic pharmaceutical market size of USD 2,455.7 million, of which Rubicon Research Limited contributed USD 195 million in Fiscal 2024. As of June 30, 2025, the company has 17 new products awaiting US FDA ANDA approval and 63 products at various stages of development. As of June 30, 2025, the company marketed over 350 SKUs to 96 customers, including three major wholesalers who account for more than 90% of wholesale drug distribution in the US. The company also supplies group purchasing organisations (GPOs), national pharmacy chains, regional pharmacy chains, and managed care organisations.

Rubicon Research Life IPO Limited Financials

The company’s financial analysis is essential before applying for the Rubicon Research IPO. Refer to the table to learn about Rubicon Research Limited’s financial information.

Year Ended	31st March 2025 (in cr.)	31st March 2024 (in cr.)	31st March 2023 (in cr.)
Assets	1,451.43	1,109.49	749.70
Revenue	1,296.22	872.39	419.00
Profit After Tax	134.36	91.01	-16.89
Net Worth	540.98	385.00	286.38
EBITDA	267.89	173.09	43.97
Reserve and Surplus	525.57	369.79	281.31
Total Borrowing	393.17	396.41	317.91

Explanation

Rubicon Research Limited’s revenue increased by 49% from ₹872.39 crore in March 2024 to ₹1,296.22 crore in March 2025. Moreover, the company’s PAT rose by 48% from ₹91.01 crores to ₹134.36 crores.

Technical Indicators

Several technical indicators are available to assess a company’s potential to deliver returns. Use the parameters mentioned below to analyse the technical aspects of the Rubicon Research Life IPO.

Key Indicators	Value
PE Ratio (Price-to-Earnings)	–
EPS (Earnings Per Share)	8.70
RoNW	29.02%
ROCE	–
ROE	29.02%
EBITDA Margin	20.02%
Price to Book Value	–
Market Capitalisation	–

Rubicon Research Life IPO Listing Expectations

Rubicon Research Life IPO Highlights: IPO allotment is still pending, as the bid closes today. However, given the current GMP or market sentiment, it is reasonable to expect higher listing gains for the share. A jump of 21.44% in the Rubicon Research Life IPO GMP suggests the estimated listing price per share will be around Rs 589.

It will provide higher listing gains to investors who applied for this IPO. Also, the financial fundamentals of this business made it the experts’ top long-term recommendation.

Rubicon Research Life IPO Dates

IPO Open Date	9th October 2025
IPO Close Date	13th October 2025
Allotment	14th October 2025
Refund Date	15th October 2025
IPO Listing Date	16th October 2025

Note: IPO GMP is volatile, driven by market sentiment. Hence, one should conduct their research before investing in it.